Sadanandan E. Velu, PhD

Dr. Velu is an Associate Professor in the Chemistry Department of University of Alabama at Birmingham. He also holds co-appointments as an Associate Scientist at the UAB Comprehensive Cancer Center and the UAB Center for Clinical and Translational Sciences. His teaching responsibilities include both undergraduate and graduate level organic and medicinal chemistry courses in the department. His research interests are in organic/medicinal chemistry, drug discovery and development, anti-cancer and anti-infective agents, structure based drug design, fragment based drug discovery, in-silico virtual screening, directed combinatorial synthesis, structure activity relationship (SAR) studies, lead optimization, solution phase parallel synthesis, synthesis of marine natural products and their analogs, development of synthetic methodologies.

Associate Professor
email
Chemistry Building 280
(205) 975-2478

Upcoming Events

Le Studium Consortium
11.04.2019 

Recent Articles

  1. Jaden Cowan, Mohammad Shadab, Dwayaja H. Nadkarni, Kailash KC, Sadanandan E. Velu (Co-corresponding author) and Nabiha Yusuf, A Novel Marine Natural Product Derived Pyrroloiminoquinone with Potent Activity against Skin Cancer Cells, Marine Drugs, 17, 1-12 (2019), PubMed PMID: 31357586, PubMed PMCID: NA, DOI: 10.3390/md17080443.

  2. Wei Wang, Jianwen Cheng, Jiang-Jiang Qin, Bo Hu, Xin Li, Bhavitavya Nijampatnam, Sadanandan E Velu, Jia Fan, Xin-Rong Yang, Ruiwen Zhang, MDM2-NFAT1 Dual Inhibitor, MA242: Effective against Hepatocellular Carcinoma, Independent of p53, Cancer Letters (2019), 459: 156-167, PubMed PMID: 31181320, PubMed PMCID: PMC6650270, DOI: 10.1016/j.canlet.2019.114429.

  3. Wei Wang, Jiang-Jiang Qin, Sukesh Voruganti, Bhavitavya Nijampatnam, Sadanandan E. Velu, Ke-He  Ruan,  Ming Hu,  Jianwei Zhou and Ruiwen Zhang, Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy, Cancer Research, 78(19): 5656-5667  (2018).  PubMed PMID:  30217928,  PMCID: PMC6435280, DOI: 10.1158/0008-5472.CAN-17-3939.

  4. Sandeep Balu Shelar, Eun-Hee Shim, Garrett J. Brinkley, Anirban Kundu, Francesca Carobbio, Tyler Poston, Jubilee Tan, Vishwas Parekh, Daniel Benson, David K. Crossman, Phillip J. Buckhaults, Dinesh Rakheja, Richard Kirkman, Yusuke Sato, Seishi Ogawa, Shilpa Dutta, Sadanandan E. Velu, Ethan Emberley, Alison Pan, Jason Chen, Tony Huang, Devin Absher, Anja Becker, Conrad Kunick, Sunil Sudarshan, Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer, Clinical Cancer Research, 24(24): 6433-6446 (2018). PubMed PMID: 30108105, PubMed PMCID: PMC6295227, DOI: 10.1158/1078-0432.CCR-18-1727.

  5. Bhavitavya NijampatnamHua Zhang,Xia Cai, Suzanne M. Michalek, Hui Wu and Sadanandan E. Velu, Inhibition of Streptococcus mutans Biofilms by the Natural Stilbene Piceatannol Through the Inhibition of Glucosyltransferases, ACS Omega 3 (7), pp 8378–8385 (2018). PubMed PMID: 30087944, PubMedPMCID: PMC6072251, DOI: 10.1021/acsomega.8b00367.

  6. Shilpa Dutta, Samuel Tanner, Frédéric Gradek, Virginie Driffort, Sébastien Roger, Katri Selander and Sadanandan E. Velu (Co-corresponding author), Wayne Brouillette, Discovery and Evaluation of nNav1.5 Sodium Channel Blockers with Potent Cell Invasion Inhibitory Activity in Breast Cancer Cells, Bioorganic and Medicinal Chemistry, 26, 2428-2436 (2018). PubMed PMID: 29673714, PubMed PMCID: PMC5935567, DOI: doi.org/10.1016/j.bmc.2018.04.003.

  7. Jeffrey W. McDonald, John E. Miller, Minjee Kim and Sadanandan E. Velu, An expedient synthesis of murrayaquinone A via a novel oxidative free radical reaction, Tetrahedron Letters, 59, 550-553 (2018). PubMed PMID: 29736091, PubMed PMCID: PMC5935454, DOI: 10.1016/j.tetlet.2018.01.007.

Group

The Science & 

Mathematics University

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey